Professor Sir Nicholas J White
Podcast interview
Artemisinin therapy for malaria
Malaria kills more than half a million people every year. Following a number of groundbreaking clinical trials, Professor Sir Nick White and his Thailand team successfully demonstrated the effectiveness of artemisinin drug therapy for malaria in adults, children and infants. He also pioneered artemisinin combination therapy, the first-line treatment for malaria worldwide.
Research groups
Colleges
Nicholas White
FRS
Professor of Tropical Medicine
- Professor at Mahidol University in Thailand
Professor White’s diverse interests include the epidemiology, pathophysiology and management of uncomplicated and severe malaria, meliodosis, enteric fever, tetanus, dengue haemorrhagic fever, Japanese encephalitis and tuberculosis. His particular interests at present include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations. and the biology of relapse in vivax malaria.
Vivax malaria
Recent publications
-
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
Tripura R. et al, (2023), The Lancet Infectious Diseases, 23, 81 - 90
-
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
Watson JA. et al, (2022), eLife, 11
-
Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study
Perrone C. et al, (2022), Wellcome Open Research, 6, 216 - 216
-
Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry
Hanpithakpong W. et al, (2022), Malaria Journal, 21
-
The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria
Srinamon K. et al, (2022), Nature Communications, 13